Papillomavirus transcripts and posttranscriptional regulation

Virology

Volumn 445, Issue 1-2, 2013, Pages 187-196

  Schwartz, Stefan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

HnRNP; HPV; MRNA; Papillomavirus; Polyadenylation; Splicing; SR protein; SRSF1

Indexed keywords

CELL PROTEIN; HUR PROTEIN; MESSENGER RNA; POLYADENYLIC ACID BINDING PROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN; PROTEIN HNRNPA1; UNCLASSIFIED DRUG; VIRUS RNA;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; GENE EXPRESSION; GENE FUNCTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMORAL IMMUNITY; IMMUNE RESPONSE; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN RNA BINDING; RNA PROCESSING; RNA STABILITY; RNA TRANSLATION; SRSF1 GENE; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; VIRUS GENE; VIRUS GENOME; WART VIRUS;

HNRNP; HPV; MRNA; PAPILLOMAVIRUS; POLYADENYLATION; SPLICING; SR PROTEIN; SRSF1;

3' UNTRANSLATED REGIONS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; KERATINOCYTES; PAPILLOMAVIRIDAE; POLYADENYLATION; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; REGULATORY SEQUENCES, RIBONUCLEIC ACID; RNA SPLICE SITES; RNA SPLICING; RNA, MESSENGER; RNA, VIRAL; TRANSCRIPTION, GENETIC;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84884349988     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.04.034     Document Type: Article

References (104)

1. 7 expression. PLoS One 2012, 7:e46412.
2. Akusjarvi G., Stevenin J. Remodelling of the host cell RNA splicing machinery during an adenovirus infection. Curr. Top. Microbiol. Immunol. 2003, 272:253-286.
3. Andrew E.M., DiMaio D. Hierarchy of polyadenylation site usage by bovine papillomavirus in transformed cells. J. Virol. 1993, 67:7705-7710.
4. Barksdale S.K., Baker C.C. The human immunodeficiency virus type 1 Rev protein and the Rev-responsive element counteract the effect of an inhibitory 5' splice site in a 3' untranslated region. Mol. Cell. Biol. 1995, 15:2962-2971.
5. Barreau C., Paillard L., Osborne H.B. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res. 2006, 33:7138-7150.
6. Berg M., DiFatta J., Hoiczyk E., Schlegel R., Ketner G. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcription unit. PNAS 2005, 102:4590-4595.
7. Bernard H.U. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antiviral Ther. 2002, 7:219-237.
8. Bodaghi S., Jia R., Zheng Z.M. Human papillomavirus type 16 E2 and E6 are RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs with suboptimal splice sites. Virology 2009, 386:32-43.
9. Carlsson A., Schwartz S. Inhibitory activity of the human papillomavirus type 1 AU-rich element correlates inversely with the levels of the elav-like HuR protein in the cell cytoplasm. Arch. Virol. 2000, 145:491-503.
10. Cheunim T., Zhang J., Milligan S.G., McPhillips M.G., Graham S.V. The alternative splicing factor hnRNP A1 is up-regulated during virus-infected epithelial cell differentiation and binds the human papillomavirus type 16 late regulatory element. Virus Res. 2008, 131:189-198.
11. Chow L.T., Broker T.R., Steinberg B.M. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010, 118:422-449.
12. Collier B., Goobar-Larsson L., Sokolowski M., Schwartz S. Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J. Biol. Chem. 1998, 273:22648-22656.
13. Collier B., Öberg D., Zhao X., Schwartz S. Specific inactivation of inhibitory sequences in the 5' end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J. Virol. 2002, 76:2739-2752.
14. Cornelissen M.T., Smits H.L., Briët M.A., van den Tweel J.G., Struyk A.P., van der Noordaa J., ter Schegget J. Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas. J. Gen. Virol. 1990, 71:1243-1246.
15. Cumming S.A., Chuen-Im T., Zhang J., Graham S.V. The RNA stability regulator HuR regulates L1 protein expression in vivo in differentiating cervical epithelial cells. Virology 2009, 383:142-149.
16. Cumming S.A., McPhillips M.G., Veerapraditsin T., Milligan S.G., Graham S.V. Activity of the human papillomavirus type 16 late negative regulatory element is partly due to four weak consensus 5' splice sites that bind a U1 snRNP-like complex. J. Virol. 2003, 77:5167-5177.
17. Cumming S.A., Repellin C.E., McPhilips M., Redford J.C., Clements J.B., Graham S.V. The human papillomavirus type 31 untranslated region contains a complex bipartite negative regulatory element. J. Virol. 2002, 76:5993-6003.
18. Deng W., Jin G., Lin B.Y., Van Tine B.A., Broker T.R., Chow L.T. mRNA splicing regulates human papillomavirus type 11 E1 protein production and DNA replication. J. Virol. 2003, 77:10213-10226.
19. Doorbar J. The papillomavirus life cycle. J. Clin. Virol. 2005, 32(Suppl 1):S7-15.
20. Fay J., Kelehan P., Lambkin H., Schwartz S. Increased expression of cellular RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J. Med. Virol. 2009, 81:897-907.
21. Felber B.K., Pavlakis G.N. Molecular biology of HIV-1: positive and negative regulatory elements important for virus expression. AIDS 1993, 7:S51-62.
22. Furth P.A., Baker C.C. An element in the bovine papillomavirus late 3' untranslated region reduces polyadenylated cytoplasmic RNA levels. J. Virol. 1991, 65:5806-5812.
23. Furth P.A., Choe W.T., Rex J.H., Byrne J.C., Baker C.C. Sequences homologous to 5' splice sites are required for the inhibitory activity of papillomavirus late 3' untranslated regions. Mol. Cell. Biol. 1994, 14:5278-5289.
24. Glahder J.A., Kristiansen K., Durand M., Vinther J., Norrild B. The early noncoding region of human papillomavirus type 16 is regulated by cytoplasmic polyadenylation factors. Virus Res. 2010, 149:217-223.
25. Goraczniak R., Gunderson S.I. The regulatory element in the 3' untranslated region of human papillomavirus 16 inhibits expression by binding CUG binding protein 1. J. Biol. Chem. 2008, 283:2286-2296.
26. Graham S.V. Papillomavirus 3' UTR regulatory elements. Front. Biosci. 2008, 13:5646-5663.
27. Ser(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes. Nucleic Acids Res. 2004, 32:4448-4461.
28. Gunderson S.I., Polycarpou-Schwarz M., Mattaj I.W. U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase. Mol. Cell 1998, 1:255-264.
29. Häfner N., Driesch C., Gajda M., Jansen L., Kirchmayr R., Runnebaum I.B., Dürst M. Integration of the HPV-16 genome does not invariably result in high levels fo viral oncogene transcripts. Oncogene 2008, 27:1610-1617.
30. Han S.P., Tang Y.H., Smith R. Functional diversity of the hnRNPs: past, present and perspectives. Biochem. J. 2010, 430:379-392.
31. Howley P.M., Lowy D.R. Papillomaviridae. Virology 2006, 2299-2354. Lippincott/The Williams & Wilkins Co. Philadelphia, Pa. fifth ed. D.M. Knipe, P.M. Howley (Eds.).
32. Hubert W.G., Laimins L.A. Human papillomavirus type 31 replication modes during the early phases of the viral life cycle depend on transcriptional and posttranscriptional regulation of E1 and E2 expression. J. Virol. 2002, 76:2263-2273.
33. Jeon S., Allen-Hoffmann B.L., Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J.Virol. 1995, 69:2989-2997.
34. Jeon S., Lambert P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. PNAS 1995, 92:1654-1658.
35. Jia R., Li C., McCoy J.P., Deng C.X., Zheng Z.M. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int. J. Biol. Sci. 2010, 6:806-826.
36. Jia R., Liu X., Tao M., Kruhlak M., Guo M., Meyers C., Baker C.C., Zheng Z.M. Control of the papillomavirus early-to-late switch by differentially expressed SRp20. J. Virol. 2009, 83:167-180.
37. Jia R., Zheng Z.M. Regulation of bovine papillomavirus type 1 gene expression by RNA processing. Front. Biosci. 2009, 14:1270-1282.
38. Johansson C., Somberg M., Li X., Backström Winquist E., Fay J., Ryan F., Pim D., Banks L., Schwartz S. HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J. 2012, 13:3212-3227.
39. Johnsen C.K., Stanley M., Norrild B. Analysis of human papillomavirus type 16 E5 oncogene expression in vitro and from bicistronic messenger RNAs. Intervirology 1995, 38:339-345.
40. Kanopka A., Mühlemann O., Petersen-Mahrt S., Estmer C., Öhrmalm C., Akusjärvi G. Regulation of adenovirus alternative RNA splicing by dephosphorylation of SR proteins. Nature 1998, 393:185-187.
41. Kaufmann I., Martin G., Friedlein A., Langen H., Keller W. Human Fip1 is a subunit of CPSF that binds to U-rich elements and stimulates poly(A) polymerase. EMBO J. 2004, 23:616-626.
42. Kennedy I.M., Haddow J.K., Clements J.B. Analysis of human papillomavirus type 16 late mRNA 3' processing signals in vitro and in vivo. J. Virol. 1990, 64:1825-1829.
43. Kennedy I.M., Haddow J.K., Clements J.B. A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J. Virol. 1991, 65:2093-2097.
44. Klumpp D., Stubenrauch F., Laimins L.A. Differential effects of the splice acceptor at nucleotide 3295 of human papillomavirus 31 on stable and transient viral replication. J. Virol. 1997, 71:8186-8194.
45. Koffa M.D., Graham S.V., Takagaki Y., Manley J.L., Clements J.B. The human papillomavirus type 16 negative regulatory RNA element interacts with three proteins that act at different posttranscriptional levels. PNAS 2000, 97:4677-4682.
46. Kozak M. Regulation of translation inititaion in eucaryotic systems. Annu. Rev. Cell Biol. 1992, 8:197-225.
47. Kudla G., Lipinski L., Caffin F., Helwak A., Zylicz M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLOS Biol. 2006, 4:933-942.
48. Lai M.C., Teh B.H., Tarn W.Y. A human papillomavirus E2 transcriptional activator. The interactions with cellular splicing factors and potential function in pre-mRNA processing. J. Biol. Chem. 1999, 274:11832-11841.
49. Liu X., Mayeda A., Tao M., Zheng Z.M. Exonic splicing enhancer-dependent selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site can be rescued in a cell lacking splicing factor ASF/SF2 through activation of the phosphatidylinositol 3-kinase/Akt pathway. J. Virol. 2003, 77:2105-2115.
50. Lopez-Urrutia E., Valdes J., Bonilla-Moreno R., Martinez-Salazar M., Martinez-Garcia M., Berumen J., Villegas-Sepulveda N. A few nucleotide polymorphisms are sufficient to recruit nuclear factors differentially to the intron 1 of HPV-16 intratypic variants. Virus Res. 2012, 166:43-53.
51. Manley J.L., Krainer A.R. A rationale nomenclature for serine/argininge-rich protein splicing factors (SR proteins). Genes Dev. 2010, 24:1073-1074.
52. McPhillips M.G., Veerapraditsin T., Cumming S.A., Karali D., Milligan S.G., Boner W., Morgan I.M., Graham S.V. SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells. J. Virol. 2004, 78:10598-10605.
53. Mole S., McFarlane M., Chuen-Im T., Milligan S.G., Millan D., Graham S.V. RNA splicing factors regulated by HPV16 during cervical tumour progression. J. Pathol. 2009, 219:383-391.
54. Mole S., Milligan S.G., Graham S.V. Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF. J. Virol. 2009, 83:357-367.
55. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 2010, 10:550-560.
56. Mori S., Ozaki S., Yasugi T., Yoshikawa H., Taketani Y., Kanda T. Inhibitory cis-element-mediated decay of human papillomavirus type 16 L1-transcript in undifferentiated cells. Mol. Cell. Biochem. 2006, 288:47-57.
57. Oberg D., Collier B., Zhao X., Schwartz S. Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells. J. Virol. 2003, 77:11674-11684.
58. Oberg D., Fay J., Lambkin H., Schwartz S. A downstream polyadenylation element in human papillomavirus type 16 encodes multiple GGG-motifs and interacts with hnRNP H. J. Virol. 2005, 79:9254-9269.
59. Orru B., Cunniffe C., Ryan F., Schwartz S. Development and validation of a novel reporter assay for human papillomavirus type 16 late gene expression. J. Virol. Methods 2012, 183:106-116.
60. Ozbun M.A. Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. J. Virol. 2002, 76:11291-11300.
61. Poppelreuther S., Iftner T., Stubenrauch F. A novel splice donor at nt 1534 is required for long-term maintenance of HPV-31 genomes. Virology 2007, 370:93-101.
62. Remm M., Remm A., Ustav M. Human papillomavirus type 18 E1 protein is translated from polycistronic mRNA by a discontinuous scanning mechanism. J.Virol. 1999, 73:3062-3070.
63. Rollman E., Arnheim L., Collier B., Öberg D., Hall H., Klingström J., Dillner J., Pastrana D.V., Buck C.B., Hinkula J., Wahren B., Schwartz S. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology 2004, 322:182-189.
64. * early mRNA is coupled to EGF signaling via Erk1/2 activation. PNAS 2010, 107:7006-7011.
65. Rush M., Zhao X., Schwartz S. A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression. J. Virol. 2005, 79:12002-12015.
66. Schmitt M., Dalstein V., Waterboer T., Clavel C., Gissman L., Pawlita M. Diagnosing cervical cancer and high-grade precursors by HPV-16 transcription patterns. Cancer Res. 2010, 70:249-256.
67. Schwartz S. HPV-16 RNA processing. Front. Biosci. 2008, 13:5880-5891.
68. Smotkin D., Prokoph H., Wettstein F.O. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J. Virol. 1989, 63:1441-1447.
69. Sokolowski M., Furneaux H., Schwartz S. The inhibitory activity of the AU-rich RNA element in the human papillomavirus type 1 late 3' untranslated region correlates with its affinity for the elav-like HuR protein. J. Virol. 1999, 73:1080-1091.
70. Sokolowski M., Schwartz S. Heterogeneous nuclear ribonucleoprotein C binds exclusively to the functionally important UUUUU-motifs in the human papillomavirus type-1 AU-rich inhibitory element. Virus Res. 2001, 73:163-175.
71. Sokolowski M., Tan W., Jellne M., Schwartz S. mRNA instability elements in the human papillomavirus type 16 L2 coding region. J. Virol. 1998, 72:1504-1515.
72. Sokolowski M., Zhao C., Tan W., Schwartz S. AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors. Oncogene 1997, 15:2303-2319.
73. Somberg M., Li X., Johansson C., Orru B., Chang R., Rush M., Fay J., Ryan F., Schwartz S. SRp30c activates human papillomavirus type 16 L1 mRNA expression via a bimodal mechanism. J. Gen. Virol. 2011, 92:2411-2421.
74. Somberg M., Rush M., Fay J., Ryan F., Lambkin H., Akusjärvi G., Schwartz S. Adenovirus E4orf4 induces HPV-16 late L1 mRNA production. Virology 2009, 383:279-290.
75. Somberg M., Schwartz S. Multiple ASF/SF2 sites in the HPV-16 E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome. J. Virol. 2010, 84:8219-8230.
76. Somberg M., Zhao X., Fröhlich M., Evander M., Schwartz S. PTB induces HPV-16 late gene expression by interfering with splicing inhibitory elements at the major late 5'-splice site SD3632. J. Virol. 2008, 82:3665-3678.
77. Stacey S.N., Jordan D., Snijders P.J.F., Mackett M., Walboomers J.M.M., Arrand J.R. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J. Virol. 1995, 69:7023-7031.
78. Tan W., Felber B.K., Zolotukhin A.S., Pavlakis G.N., Schwartz S. Efficient expression of the human papillomavirus type 16 L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type 1. J. Virol. 1995, 69:5607-5620.
79. Tan W., Schwartz S. The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3' untranslated region. J. Virol. 1995, 69:2932-2945.
80. *I transcripts in high-risk human papillomavirus type 16- or 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 2006, 80:4249-4263.
81. Terhune S.S., Hubert W.G., Thomas J.T., Laimins L.A. Early polyadenylation signals of human papillomavirus type 31 negatively regulate capsid gene expression. J. Virol. 2001, 75:8147-8157.
82. Terhune S.S., Milcarek C., Laimins L.A. Regulation of human papillomavirus 31 polyadenylation during the differentiation-dependent life cycle. J. Virol. 1999, 73:7185-7192.
83. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology 2009, 384:375-379.
84. Tomita Y., Simizu B. Translational properties of the human papillomavirus type-6 L1-coding mRNA. Gene 1993, 133:223-225.
85. Valente S.T., Gilmartin G.M., Venkatarama K., Arriagada G., Goff S.P. HIV-1 mRNA 3' end processing is distinctively regulated by eIF3f, CDK11, and splice factor 9G8. Mol. Cell 2009, 36:279-289.
86. Vinther J., Rosenstierne M.W., Kristiansen K., Norrild B. The 3' region of human papillomavirus type 16 early mRNAs decrease expression. BMC Infect. Dis. 2005, 5:83.
87. Wiklund L., Sokolowski M., Carlsson A., Rush M., Schwartz S. Inhibtion of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability in the HPV-1 late 3' untranslated region. J. Biol. Chem. 2002, 277:40462-40471.
88. Xue Y., Bellanger S., Zhang W., Lim D., Low J., Lunny D., Thierry F. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res. 2010, 70:5316-5325.
89. Zhao C., Tan W., Sokolowski M., Schwartz S. Identification of nuclear and cytoplasmic factors that interact specifically with an AU-rich, cis-acting inhibitory sequence in the 3' untranslated region of human papillomavirus type 1 late mRNAs. J. Virol. 1996, 70:3659-3667.
90. Zhao K.N., Gu W., Fang N.X., Saunders N.A., Frazer I.H. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol. Cell. Biol. 2005, 19:8643-8655.
91. Zhao X., Fay J., Lambkin H., Schwartz S. Identification of a 17-nucleotide splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP A1-binding splicing silencers. Virology 2007, 369:351-363.
92. Zhao X., Öberg D., Rush M., Fay J., Lambkin H., Schwartz S. A 57 nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2 and PTB. J. Virol. 2005, 79:4270-4288.
93. Zhao X., Rush M., Carlsson A., Schwartz S. The presence of inhibitory RNA elements in the late 3'-untranslated region is a conserved property of human papillomaviruses. Virus Res. 2007, 125:135-144.
94. Zhao X., Rush M., Schwartz S. Identification of an hnRNP A1 dependent splicing silencer in the HPV-16 L1 coding region that prevents premature expression of the late L1 gene. J. Virol. 2004, 78:10888-10905.
95. Zhao X., Schwartz S. Inhibition of HPV-16 L1 expression from L1 cDNAs correlates with the presence of hnRNP A1 binding sites in the L1 coding region. Virus Genes 2008, 36:45-53.
96. Zheng Z.M., Baker C.C. Papillomavirus genome structure, expression, and posttranscriptional regulation. Front. Biosci. 2006, 11:2286-2302.
97. Zheng Z.M., He P., Baker C.C. Selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site is regulated through an exonic splicing enhancer and its juxtaposed exonic splicing suppressor. J. Virol. 1996, 70:4691-4699.
98. Zheng Z.M., He P.J., Baker C.C. Structural, functional, and protein binding analyses of bovine papillomavirus type 1 exonic splicing enhancers. J. Virol. 1997, 71:9096-9107.
99. Zheng Z.M., He P.J., Baker C.C. Function of a bovine papillomavirus type 1 exonic splicing suppressor requires a suboptimal upstream 3' splice site. J. Virol. 1999, 73:29-36.
100. Zheng Z.M., Huynen M., Baker C.C. A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly. PNAS 1998, 95:14088-14093.
101. Zheng Z.M., Quintero J., Reid E.S., Gocke C., Baker C.C. Optimization of a weak 3' splice site counteracts the function of a bovine papillomavirus type 1 exonic splicing suppressor in vitro and in vivo. J. Virol. 2000, 74:5902-5910.
102. Zheng Z.M., Reid E.S., Baker C.C. Utilization of the bovine papillomavirus type 1 late-stage-specific nucleotide 3605 3' splice site is modulated by a novel exonic bipartite regulator but not by an intronic purine-rich element. J. Virol. 2000, 74:10612-10622.
103. Zheng Z.Z., Sun Y.Y., Zhao M., Huang H., Zhang J., Xia N.S., Miao J., Zhao Q. Specific interaction between hnRNP H and HPV16 L1 proteins: Implications for late gene auto-regulation enabling rapid viral capsid protein production. Biochem. Biophys. Res. Commun. 2012, 430:1047-1053.
104. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.